Compared with mutational profiling routinely analyzed using tumor samples, TP53, SMAD4, APC, AKT1, GNAS, IDH1, IDH2, and PDGFRA mutations were the additional mutations identified by this cfDNA assay. This evidence concerns the gene IDH2 and neoplasm.